Abstract | BACKGROUND & AIMS: METHODS: A total of 539 patients with active Crohn's disease and secondary failure to infliximab were enrolled in a 26-week trial. Patients received open-label induction with subcutaneous certolizumab pegol 400 mg at weeks 0, 2, and 4. Those in clinical response at week 6 were randomized to certolizumab pegol 400 mg every 2 or every 4 weeks through week 24. The primary end point was response at week 6. Secondary end points included remission at week 6 and response and remission at week 26. RESULTS: At week 6, 334 of 539 patients (62.0%) achieved response and 212 of 539 (39.3%) achieved remission. A total of 329 patients were randomized and received maintenance therapy. At week 26, 39.9% (67 of 168) and 36.6% (59 of 161) of patients in the every-4-weeks and every-2-weeks groups were in clinical response, respectively (P = .55). Corresponding remission rates at week 26 were 29.2% and 30.4%, respectively (P = .81). Serious infections occurred in 9 of 539 (1.7%) and 12 of 373 (3.2%) of patients during induction and maintenance, respectively. A single malignancy (skin carcinoma) occurred in a patient receiving every-4-weeks maintenance therapy. CONCLUSIONS:
|
Authors | William J Sandborn, Maria T Abreu, Geert D'Haens, Jean-Frédéric Colombel, Severine Vermeire, Krassimir Mitchev, Corinne Jamoul, Richard N Fedorak, Martina E Spehlmann, Douglas C Wolf, Scott Lee, Paul Rutgeerts |
Journal | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
(Clin Gastroenterol Hepatol)
Vol. 8
Issue 8
Pg. 688-695.e2
(Aug 2010)
ISSN: 1542-7714 [Electronic] United States |
PMID | 20451663
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Copyright | Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Immunoglobulin Fab Fragments
- Immunologic Factors
- Polyethylene Glycols
- Infliximab
- Certolizumab Pegol
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal
(therapeutic use)
- Antibodies, Monoclonal, Humanized
- Certolizumab Pegol
- Crohn Disease
(drug therapy)
- Female
- Humans
- Immunoglobulin Fab Fragments
(therapeutic use)
- Immunologic Factors
(therapeutic use)
- Infliximab
- Male
- Middle Aged
- Polyethylene Glycols
(therapeutic use)
- Treatment Outcome
- Young Adult
|